Richard H. Stanford, PharmD, MS

Articles by Richard H. Stanford, PharmD, MS

COPD Exacerbation Costs in the IMPACT Study: A Within-Trial Analysis

ByMichael R. Bogart, PharmD,Sari D. Hopson, PhD, MSPH,Huai-Che Shih, PhD,Richard H. Stanford, PharmD, MS,Anna D. Coutinho, PhD, BPharm

May 6th 2020

Treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with FF/VI or UMEC/VI reduced exacerbation-related costs associated with chronic obstructive pulmonary disease (COPD) in the US healthcare system.

Cost Analysis of COPD Exacerbations and Cardiovascular Events in SUMMIT

ByRichard H. Stanford, PharmD, MS,Anna D. Coutinho, PhD,Michael Eaddy, PharmD, PhD,Binglin Yue, MS,Michael Bogart, PharmD

November 18th 2019

This cost analysis using data from the Study to Understand Mortality and Morbidity in COPD (SUMMIT) trial found that fluticasone furoate/vilanterol reduced the rates and costs of combined chronic obstructive pulmonary disease (COPD) exacerbations and revascularization/cardiovascular events versus placebo.

Claims-Based Risk Model for First Severe COPD Exacerbation

ByRichard H. Stanford, PharmD, MS,Arpita Nag, PhD, MBA, MS,Douglas W. Mapel, MD,Todd A. Lee, PhD,Richard Rosiello, MD,Michael Schatz, MD,Francis Vekeman, MS,Marjolaine Gauthier-Loiselle, PhD,J.F. Philip Merrigan, PhD,Mei Sheng Duh, ScD

February 17th 2018

A health insurance claims-based risk assessment tool to predict patients’ first severe chronic obstructive pulmonary disease exacerbation has been developed and validated.

Predicting Asthma Outcomes in Commercially Insured and Medicaid Populations

ByRichard H. Stanford, PharmD, MS,Manan B. Shah, PharmD, PhD,Anna O. D'Souza, BPharm, PhD,Michael Schatz, MD, MS

January 22nd 2013

The controller-to-total asthma medication ratio was a significant predictor of exacerbations in pediatric and adult commercially insured and Medicaid patients.